Blood Screening Market

Emergence of automated molecular platforms for blood screening to propel market growth

Automated molecular platforms for blood screening are becoming a popular strategy among leading market players, fueling market growth. Blood screening tests aim to ensure the security of donated blood units and to find any signs of transmissible transfusion infections (TTIs) in the blood. The transition from manual to automated screening platforms has been critical in identifying contagious transfusion infections (TTIs) in blood samples. In the transfusion screening process, growing automation is anticipated to reduce human error. These screening tests generally impact most medical decisions in blood banks and hospitals.

For instance, F. Hoffmann-La Roche Ltd. confirmed the CE-IVD launch of "cobas" in December 2019, which is intended to be utilized for blood donation screening and locates the Zika virus in human plasma. As a result, the adoption of these automated molecular platforms in blood donation facilities has increased due to the introduction of these platforms by key players. This will drive the growth of the blood screening market CAGR over the forecasted period.

Other key factors boosting the development of the Blood Screening Market revenue include increasing blood donations and blood donors, raising awareness of the safety of donated blood, growing the prevalence of infectious diseases, and various government initiatives. The number of blood donations worldwide in 2022 is estimated to be around 118.5 million. Additionally, the WHO suggests that blood donations be screened for illnesses before use, including hepatitis B, syphilis, and other sexually transmitted diseases (STDs).

The increasing incidence of bloodborne diseases such as HIV, Hepatitis B, and Hepatitis C is a primary driver for the Global Blood Screening Market Industry. As awareness regarding these diseases grows, the demand for effective screening methods intensifies. For instance, the World Health Organization reports that millions are affected globally, necessitating robust screening protocols. This heightened focus on disease prevention is projected to contribute significantly to the market's growth, with the industry expected to reach 3.4 USD Billion in 2024 and potentially 7.49 USD Billion by 2035, reflecting a compound annual growth rate of 7.45% from 2025 to 2035.

By Region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American Blood Screening market accounted for USD 1.14 billion in 2022 and is likely to exhibit a significant CAGR growth over the study period. The region's largest share is mainly attributed to rising blood transfusion-related screenings, increasing infectious disease prevalence, an aging population, the need for early disease detection and monitoring, rising healthcare expenditure, and the growing adoption of technologically advanced blood screening technologies.

This region's dominance is further attributed to increased blood donors, widespread implementation of blood screening procedures, and improved patient affordability.

Further, the major countries studied in the global market report are the U.S., Germany, Canada, France, the UK, Spain, Italy, Japan, India, Australia, China, South Korea, and Brazil.

Figure 3: BLOOD SCREENING MARKET SHARE BY REGION 2022 (%)

Source: Primary Research, Secondary Research, Market Research Future Database, and Analyst Review

The second-largest market share belongs to the European blood screening market, where respiratory illnesses and cancer are becoming more common. Rising government support and increased private-sector investment in the research and development of various blood screening tests are driving revenue growth in this region. For instance, F. Hoffmann-La Roche Ltd. introduced the Cobas Zika test for Cobas 6800/8800 Systems on December 16, 2019. The Cobas Zika test is designed to screen blood donations in Europe for Zika virus infection by finding RNA in human plasma samples.

In addition, the European Union has made blood screening for HCV, HBV, HIV, parvovirus-19, and other viruses mandatory. Further, the German blood screening market held the largest market share, and the UK blood screening market was the fastest-growing market in the European region.

The Asia-Pacific Blood Screening Market is projected to grow at the fastest CAGR from 2024 to 2032, owing to rising patient affordability and key industry players' increased focus on emerging markets. Japan, India, China, Singapore, and Australia contribute significantly to the market in the Asia Pacific region. Moreover, China’s blood screening market held the largest market share, and the Indian blood screening market was the fastest-growing market in the Asia-Pacific region.

India's blood screening market differs from other Asia Pacific nations like China and Japan as of laxer regulatory requirements and the importation of the necessary equipment and materials. Expanded investments by private and international entities, which may help offer practical tests at lower prices, are expected to lead to significant growth in the Indian blood screening industry. India's well-connected network of clinical laboratories and healthcare facilities is accelerating the adoption of blood screening methods.

The competitive landscape is semi-consolidated, with several domestic and international blood screening industry players operating globally. Major market players are investing heavily in research and development to develop more innovative and advanced techniques that minimize turnaround time and improve the effectiveness and accuracy of crossmatch screening. Key players use various market development strategies, including investing in adapting cutting-edge techniques, launching new technologies, mergers & acquisitions, and regional expansion to capture the largest share of global revenue.

Blood screening industry competitors must provide cost-effective products and services to develop and sustain in an intensely challenging and rising global market environment. The blood screening market major players, such as BioMerieux, Siemens Healthineers, Thermo Fisher Scientific Inc, and others, are working to increase industry demand by investing in research and development activities to ensure constant innovation. The global blood screening industry has recently provided some of the most substantial advantages to reagents and instruments.

Roche Diagnostics (Switzerland) is a company that provides diagnostic system solutions for hospitals, clinics, laboratories, and doctors' offices. The company creates, manufactures, and supports in-vitro diagnostic and bioanalytical instruments and software systems. It also provides test systems, molecular diagnostic reagents, blood screening products, diagnostic analysis systems, and workflow solutions. Blood glucose meters and point-of-care testing equipment are among its primary offerings. The company offers services and products to commercial diagnostic laboratories, hospitals, researchers, healthcare professionals, and pharmacists. Roche Diagnostics (Switzerland) purchased TIB Molbiol Group (Germany) in September 2021.

This acquisition will broaden Roche's portfolio of molecular diagnostics solutions, including assays for infectious diseases, such as identifying SARS-CoV-2 variants.

Also, Becton, Dickinson, and Company, or BD, is a multinational clinical technology company based in the United States that produces and distributes medical devices, indicator systems, and reagents. Additionally, in certain regions, BD offers consulting and analytics services. In March 2020, B.D. announced the launch of a singular blood screening test that can identify antibodies in blood to confirm current or previous COVID-19 exposure in less than 15 minutes.